Simcere Pharmaceutical Group Limited
HKEX:2096.HK
6.16 (HKD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 6,607.805 | 6,319.096 | 4,999.718 | 4,508.72 | 5,036.658 | 4,514.204 | 3,867.908 | 2,082.966 |
| Cost of Revenue
| 1,623.652 | 1,322.246 | 1,079.983 | 899.927 | 888.486 | 771.195 | 586.301 | 361.071 |
| Gross Profit
| 4,984.153 | 4,996.85 | 3,919.735 | 3,608.793 | 4,148.172 | 3,743.009 | 3,281.607 | 1,721.895 |
| Gross Profit Ratio
| 0.754 | 0.791 | 0.784 | 0.8 | 0.824 | 0.829 | 0.848 | 0.827 |
| Reseach & Development Expenses
| 1,563.138 | 1,728.269 | 1,416.721 | 1,141.996 | 716.412 | 447.148 | 212.309 | 228.717 |
| General & Administrative Expenses
| 487.829 | 444.201 | 382.485 | 411.476 | 142.601 | 129.74 | 126.92 | 255.999 |
| Selling & Marketing Expenses
| 2,356.386 | 2,402.371 | 2,036.705 | 1,570.373 | 2,016.222 | 2,221.757 | 2,155.662 | 1,140.81 |
| SG&A
| 2,844.215 | 2,846.572 | 2,419.19 | 1,981.849 | 2,158.823 | 2,351.497 | 2,282.582 | 1,396.809 |
| Other Expenses
| 5.07 | -154.522 | -132.16 | -104.935 | 132.766 | 12.05 | 5.024 | 0 |
| Operating Expenses
| 4,257.652 | 4,420.319 | 3,703.751 | 3,018.91 | 3,008.001 | 2,903.619 | 2,580.113 | 1,676.687 |
| Operating Income
| 711.802 | 862.505 | 687.9 | 565.665 | 1,171.31 | 941.941 | 530.579 | 96.369 |
| Operating Income Ratio
| 0.108 | 0.136 | 0.138 | 0.125 | 0.233 | 0.209 | 0.137 | 0.046 |
| Total Other Income Expenses Net
| 7.6 | 25.649 | 713.897 | 239.423 | -89.495 | 88.345 | -251.236 | -116.353 |
| Income Before Tax
| 740.038 | 888.154 | 1,401.797 | 805.088 | 1,081.815 | 929.044 | 497.284 | -19.984 |
| Income Before Tax Ratio
| 0.112 | 0.141 | 0.28 | 0.179 | 0.215 | 0.206 | 0.129 | -0.01 |
| Income Tax Expense
| 26.088 | -40.478 | -97.124 | 140.801 | 78.191 | 195.357 | 146.872 | 5.581 |
| Net Income
| 714.761 | 930.868 | 1,507.096 | 669.534 | 1,003.624 | 733.687 | 350.409 | 56.957 |
| Net Income Ratio
| 0.108 | 0.147 | 0.301 | 0.148 | 0.199 | 0.163 | 0.091 | 0.027 |
| EPS
| 0.27 | 0.4 | 0.58 | 0.26 | 0.39 | 0.28 | 0.13 | 0.53 |
| EPS Diluted
| 0.27 | 0.4 | 0.58 | 0.26 | 0.39 | 0.28 | 0.13 | 0.53 |
| EBITDA
| 1,090.686 | 1,088.977 | 939.707 | 787.994 | 1,342.705 | 1,015.891 | 825.486 | 227.953 |
| EBITDA Ratio
| 0.165 | 0.172 | 0.188 | 0.175 | 0.267 | 0.225 | 0.213 | 0.109 |